MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
11.03
-1.13
-9.29%
After Hours: 11.04 +0.01 +0.09% 16:55 10/02 EDT
OPEN
12.08
PREV CLOSE
12.16
HIGH
12.16
LOW
10.94
VOLUME
3.60M
TURNOVER
0
52 WEEK HIGH
14.10
52 WEEK LOW
9.10
MARKET CAP
3.17B
P/E (TTM)
-17.3074
1D
5D
1M
3M
1Y
5Y
Amicus Therapeut: Report of proposed sale of securities
Press release · 4h ago
Amicus in pact with Blackstone for $430M financing
Seeking Alpha · 11h ago
Amicus Therapeut: Current report
Press release · 12h ago
Amicus Therapeutics And Blackstone Enter Into $430M Strategic Financing Collaboration; Blackstone To Also Purchase $30M Of Amicus Common Stock
Benzinga · 12h ago
Weekly Report: what happened at FOLD last week (0925-0929)?
Weekly Report · 15h ago
JP Morgan Maintains Amicus Therapeutics (FOLD) Overweight Recommendation
NASDAQ · 2d ago
Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter
Seeking Alpha · 3d ago
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
NASDAQ · 3d ago
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.